🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
48 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I/II
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
2025-522295-91-00relapsed or refractory Waldenstrom’s macroglobulinemia
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Denmark, Belgium, Netherlands
10/03/2026
Phase I/II
Late immunity following single immunization with GA2 sporozoites (GACHA)
2025-524045-27-00Falciparum malaria
Leids Universitair Medisch Centrum (LUMC)
Parasitic Diseases
Netherlands
09/03/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase I/II
A Phase 1 Study of Fentanyl Vaccine
2025-524277-16-00Opioid induced respiratory depression
ARMR Sciences Inc.
Environment and Public Health
Netherlands
23/02/2026
Phase I/II
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posi…
Amgen Inc.
Neoplasms
France, Netherlands, Italy
13/02/2026
Phase I/II
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D
2025-522253-19-00Urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, France, Spain
03/02/2026
Phase I/II
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis
2025-522039-33-00Amyotrophic Lateral Sclerosis
Leal Therapeutics Inc.
Nervous System Diseases
Sweden, Italy, Germany, Netherlands
23/01/2026
Phase I/II
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
2025-521973-16-00Netherton Syndrome
Biocryst Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
France, Netherlands, Germany
20/01/2026
Phase I/II
Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)
2025-521420-30-00Inflammatory Bowel Disease (IBD)
Universitair Medisch Centrum Groningen
Digestive System Diseases
Netherlands
06/01/2026
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase I/II
SPRAYDYE-Trial - A phase I/II study to assess the efficacy, safety and tolerability of topically applied 6qc-ICG, a cathepsin-activatable fluorescent probe, for real-time intraoperative resection margin assessment in breast conserving surgery
2025-523166-24-00Breast cancer
Leids Universitair Medisch Centrum (LUMC)
Neoplasms
Netherlands
22/12/2025
Phase I/II
A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)
2023-507597-40-00B-cell precursor ALL, B-cell Non Hodgkin Lymphoma
Prinses Maxima Centrum voor Kinderoncologie B.V.
Neoplasms
Netherlands
16/12/2025
Phase I/II
Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Patients with Hormone Sensitive Prostate Cancer. - The DARO-flare Trial -
2025-520482-52-03Prostate cancer
Amsterdam UMC Stichting
Diagnosis
Netherlands
04/12/2025
Phase I/II
OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer
2025-522659-24-00Ovarian carcinoma
Leids Universitair Medisch Centrum (LUMC)
Neoplasms
Netherlands
03/12/2025
Phase I/II
An open-label, non-randomized, extension study to further investigate the long-term efficacy, safety, and tolerability of Guanabenz in patients with early childhood onset vanishing white matter (VWM)
2024-518834-95-02Vanishing white matter
Amsterdam UMC Stichting
Nervous System Diseases
Netherlands
21/11/2025
Phase I/II
A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors
2025-521441-24-00Advanced or Metastatic Solid Tumors
Alentis Therapeutics AG
Neoplasms
Spain, France, Netherlands, Italy
12/11/2025
Phase I/II
(22931) A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.
2025-520623-24-00MTAP-deleted Solid Tumors
Bayer AG
Neoplasms
Belgium, Sweden, Denmark, Italy, Spain, Netherlands, Czechia
04/11/2025
Phase I/II
The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy
2025-521163-12-01Graves' Orbitopathy
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Immune System Diseases
Netherlands
30/10/2025
Phase I/II
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).
2024-511508-18-00Chronic graft versus host disease.
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
France, Italy, Belgium, Spain, Netherlands, Germany
30/09/2025
Phase I/II
A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC)
2024-514360-70-00Low-grade upper track urothelial carcinoma (LG-UTUC)
Ferring Pharmaceuticals A/S
Female Urogenital Diseases and Pregnancy Complications
Spain, France, Netherlands
16/09/2025
Phase I/II
A Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A), for the Treatment of Ventilator-Associated Pneumonia
2025-521533-85-00Ventilator-Associated Pneumonia
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.
Bacterial Infections and Mycoses
Portugal, Netherlands
09/09/2025
Phase I/II
BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial
2024-515900-38-00B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-…
Leids Universitair Medisch Centrum (LUMC)
Neoplasms
Netherlands
28/08/2025
Phase I/II
A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
2025-520672-26-00Gastrointestinal Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Belgium, Italy, Norway, Finland, Poland, Netherlands, Germany, Spain, France, Sweden
27/08/2025
Rows per page Showing 26–48 of 48
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.